Notcutt on N=1 Trials

From O’Shaughnessy’s report on the International Cannabinoid Research Society’s 2002 meeting: William Notcutt recounted that he and colleagues at the James Paget Hospital in Great Yarmouth used Sativex —GW Pharmaceuticals’ extract formulated for spraying under the tongue— in clinical trials involving 29 chronic pain patients. Initially patients were given a 1:1 mix of THC and CBD for two weeks. The 27 who reported benefits than received, over the next eight weeks, one-week treatments with high-THC, high-CBD, placebo, and 1:1 THC/CBD extracts. The order in which patients used the various extracts was unknown to either them or the doctors. This method, in which...

Read More